Insider Trading Alert - DGX, CELG And HPQ Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 5, 2014, 233 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.59 to $85,937,500.00.

Highlighted Stocks Traded by Insiders:

Quest Diagnostics (DGX) - FREE Research Report

Prevoznik Michael E who is SVP & General Counsel at Quest Diagnostics sold 778 shares at $53.00 on March 5, 2014. Following this transaction, the SVP & General Counsel owned 43,212 shares meaning that the stake was reduced by 1.77% with the 778-share transaction.

The shares most recently traded at $52.59, down $0.41, or 0.78% since the insider transaction. Historical insider transactions for Quest Diagnostics go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 3,687
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 3,687
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 6,345

The average volume for Quest Diagnostics has been 2.6 million shares per day over the past 30 days. Quest Diagnostics has a market cap of $7.5 billion and is part of the health care sector and health services industry. Shares are down 2.39% year-to-date as of the close of trading on Wednesday.

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. The stock currently has a dividend yield of 2.53%. The company has a P/E ratio of 9.8. Currently there are 2 analysts that rate Quest Diagnostics a buy, 4 analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DGX - FREE

TheStreet Quant Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, notable return on equity, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Quest Diagnostics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Cramer: These Sectors Look Bullish (Part III)

Cramer: There Are Powerful Themes in Several Bull Markets

Stanley Black & Decker, Quest Diagnostics and 2 More Could Rocket Higher This Spring -- Here's Why

MasterCard, Intuitive Surgical and 2 More Could Rocket Higher This Spring--Here's Why …

Market Recon: If You Are Scared, Don't Show It